Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 2

Status

Suspended 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 6INDUSTRY 5

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

CNS 3Plasma cell 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Glioma 2Pancreatic Ductal Adenocarcinoma 1Multiple Myeloma 1Melanoma 1Glioblastoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 593Cyclophosphamide 539Magnetic Resonance Spectroscopy 527Radiotherapy 506Specimen Handling 504Nivolumab 406Cisplatin 370Carboplatin 360Biopsy 306Blood Specimen Collection 296Radiosurgery 284Paclitaxel 276Surveys and Questionnaires 269Standard of Care 267Gemcitabine 266fludarabine 261Dexamethasone 258Drug Therapy 256Bevacizumab 248venetoclax 247Oxaliplatin 206Rituximab 197Capecitabine 194Radiation 190Fluorouracil 186Ipilimumab 183durvalumab 181Doxorubicin 174atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Glucose × 1 year × Clear all
NCT06391099 2026-05-26

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Ohio State University Comprehensive Cancer Center

Phase NA Suspended
60 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT07091864 2026-05-07

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Mayo Clinic

Phase NA Recruiting
116 enrolled
CNS

Glioblastoma

NCT05296421 2026-05-04

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

Rutgers, The State University of New Jersey

Phase NA Recruiting
16 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT02253316 2025-11-10

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Washington University School of Medicine

Phase 2 Active not recruiting
236 enrolled 13 charts
Plasma cell

Multiple Myeloma

NCT06855628 2025-10-28

Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

Stanford University

Phase 2 Suspended
10 enrolled
CNS

Glioma

NCT06594315 2025-09-18

Assessing Brain Metabolism Using MRS With Deuterated Glucose

University of California, San Francisco

Active not recruiting
80 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡